| Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial | |
| Wu, Yi-Long; Lu, Shun; Cheng, Ying; Zhou, Caicun; Wang, Jie; Mok, Tony; Zhang, Li; Tu, Hai-Yan; Wu, Lin; Feng, Jifeng | |
| 刊名 | JOURNAL OF THORACIC ONCOLOGY
 |
| 2019 | |
| 卷号 | 14期号:5 |
| 关键词 | Chinese population Nivolumab NSCLC Phase III clinical study |
| ISSN号 | 1556-0864 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3596106 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Wu, Yi-Long,Lu, Shun,Cheng, Ying,et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial[J]. JOURNAL OF THORACIC ONCOLOGY,2019,14(5). |
| APA | Wu, Yi-Long.,Lu, Shun.,Cheng, Ying.,Zhou, Caicun.,Wang, Jie.,...&Chang, Jianhua.(2019).Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.JOURNAL OF THORACIC ONCOLOGY,14(5). |
| MLA | Wu, Yi-Long,et al."Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial".JOURNAL OF THORACIC ONCOLOGY 14.5(2019). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论